Asha Therapeutics is happy to announce the appointment of Dr. Craig Blackstone as a member of its Board of Administrators and as Chair of the Scientific Advisory Board.
Asha Therapeutics (Asha) is a neuro-centric biotechnology firm which focuses solely on de novo drug discovery and chemical design, leveraging the flexibility of its disruptive PRISM™ expertise platform to develop novel therapeutics for neurological ailments with excessive unmet medical want.
Every compound in Asha Therapeutics’ pipeline is designed to revive mobile well being at a pivotal juncture of neuronal downturn. This has resulted in a sturdy, holistic asset portfolio that treats neurological illness by contemplating neuronal deterioration and loss from a number of vantage factors. Inside Asha’s pipeline, lead asset ASHA-091 is a close to clinic-ready, custom-designed, mind penetrant compound that restores the mitochondrial community, selling cell survival over cell loss of life in quite a lot of neurological situations.
Sam Shrivastava, Asha’s Founder and CEO, famous, “Dr. Blackstone is a worldwide thought chief and extremely completed doctor and clinician dedicated to cutting-edge scientific innovation with the potential to rework affected person outcomes. Dr. Blackstone’s management driving pioneering scientific inquiry within the space of neurodegenerative ailments, for which present therapeutics largely tackle the mitigation of signs moderately than arrest the supply of the illness itself, can be invaluable as Asha develops its pipeline with lead property demonstrating strong preclinical efficacy and security in lead indications and extra fashions of neurological dysfunction together with Parkinson’s Illness, Alzheimer’s Illness, Ischemic Stroke, and ALS.”
Reflecting on his new place at Asha Therapeutics, Dr. Blackstone commented, “I’m privileged to affix the Board of Administrators of Asha Therapeutics and look ahead to working with their cohesive and extremely progressive crew. I’ve been very impressed with Asha’s capacity to quickly develop a number of, extremely vital compounds utilizing their proprietary physics-based and AI-driven PRISM™ platform. These property are poised to enter medical research quickly, offering desperately wanted new first-in-class therapies and hope for many individuals with devastating neurodegenerative and oncologic issues.”
Dr. Craig Blackstone is Chief of the Motion Problems Division on the Massachusetts Normal Hospital and Professor of Neurology at Harvard Medical College. He acquired B.S./M.S. levels from the College of Chicago and M.D./Ph.D. levels from Johns Hopkins. After neurology residency within the Harvard-Longwood Neurology Program, Dr. Blackstone pursued medical fellowship coaching in motion issues at Massachusetts Normal Hospital and postdoctoral analysis coaching in neurobiology with Dr. Morgan Sheng at Harvard Medical College and the Howard Hughes Medical Institute. In 2001, Dr. Blackstone joined the NINDS, the place he remained for 20 years, rising to Senior Investigator and Cell Biology Part Chief. His group investigated the mobile and molecular mechanisms underlying hereditary motion issues. He’s an elected member of the American Society for Scientific Investigation, Affiliation of American Physicians, and Nationwide Academy of Medication in addition to an elected Fellow and former Vice President of the American Neurological Affiliation (ANA). He has held quite a few different management positions within the ANA, together with on its Government Council, Training Innovation Committee, Nominations Committee, and Skilled Growth Committee, in addition to Director of its Translational and Scientific Analysis Course and Chair of its Internet Governance Committee. Dr. Blackstone at the moment serves on the editorial board of the Journal of Scientific Investigation. He acquired the NIH Director’s Ruth L. Kirschstein Mentoring Award in 2012 and the NINDS Director’s Range Achievement Award in 2018.